Our results were not inconsistent with previous reports that αβT‐cell therapy improves OS and progression‐free survival by promoting tumor‐directed cytotoxic activity due to increasing the number of CD8+ T cells in peripheral blood, and releasing the immunosuppressive environment by decreasing the frequency of Tregs.11, 12. The gene discussed is CD8A; the disease is neoplasm.